Abstract | PURPOSE: DESIGN: RESULTS: A uniform definition of menopause and CRA is lacking. The wide range of CRA rates reported in adjuvant chemotherapy trials is a result, at least in part, of this problem. The average CRA rate reported in regimens based on cyclophosphamide, methotrexate, and fluorouracil (CMF) is 68% (95% confidence interval [CI], 66% to 70%), with a range of 20% to 100%. CRA incidence varies with age, cytotoxic agent, and cumulative dose. CONCLUSION: Ovarian damage is the most significant long-term sequela of adjuvant chemotherapy in premenopausal breast cancer survivors. We suggest a common definition of the following important terms: menopausal status, CRA (early and late), temporary CRA, and oligomenorrhea in the setting of adjuvant treatment. With uniform definitions in place, regimens can be more precisely compared with respect to this important complication.
|
Authors | J Bines, D M Oleske, M A Cobleigh |
Journal | Journal of clinical oncology : official journal of the American Society of Clinical Oncology
(J Clin Oncol)
Vol. 14
Issue 5
Pg. 1718-29
(May 1996)
ISSN: 0732-183X [Print] United States |
PMID | 8622093
(Publication Type: Journal Article, Review)
|
Topics |
- Breast Neoplasms
(drug therapy)
- Chemotherapy, Adjuvant
(adverse effects)
- Female
- Humans
- Incidence
- Menopause, Premature
(drug effects)
- Menstruation Disturbances
(chemically induced)
- Ovary
(drug effects, physiology)
|